Newron Pharmaceuticals SpA (CH:NWRN)
:NWRN
Want to see CH:NWRN full AI Analyst Report?
Top Page
Newron Pharmaceuticals SpA
(NWRN)
Select Model
Select Model
Rating:50Neutral
Price Target:
CHF12.00
▼(-27.01% Downside)
Action:Reiterated
Date:03/26/26
The score is held back mainly by weak/volatile financial performance (sharp 2025 revenue decline, losses, and a highly leveraged balance sheet with negative equity) and bearish technicals. Offsetting this, the latest earnings call conveyed strong clinical/program momentum and improved liquidity runway via the Eisai deal and deferred debt service, which meaningfully supports the outlook despite execution and conditional-funding risks.
Positive Factors
Strategic partnership & funding
The Eisai licensing deal delivered EUR 48m upfront and access to up to EUR 38m more (EUR 15m already in bank, EUR 11m expected), and deferred EIB repayments. This materially improves near-term non-dilutive runway, lowering immediate refinancing risk and enabling execution of pivotal trials.
Negative Factors
Elevated balance-sheet risk
Negative equity and high leverage constrain strategic flexibility: refinancing or additional M&A/partnering options become harder, and downside shocks increase dilution/refinancing risk. This structural weakness limits the firm's ability to self-fund commercialization or absorb trial setbacks over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic partnership & funding
The Eisai licensing deal delivered EUR 48m upfront and access to up to EUR 38m more (EUR 15m already in bank, EUR 11m expected), and deferred EIB repayments. This materially improves near-term non-dilutive runway, lowering immediate refinancing risk and enabling execution of pivotal trials.
Read all positive factors
Newron Pharmaceuticals SpA (NWRN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF254.25M
Dividend YieldN/A
Average Volume (3M)170.30K
Price to Earnings (P/E)―
Beta (1Y)1.92
Revenue Growth-63.05%
EPS Growth-187.61%
CountryCH
Employees22
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding20,805,798
10 Day Avg. Volume255,106
30 Day Avg. Volume170,297
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-45.95
Price to Sales (P/S)26.73
P/FCF Ratio15.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF44.00Price Target Upside167.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.97
Revenue Forecast (FY)CHF24.62M
Newron Pharmaceuticals SpA Business Overview & Revenue Model
Company Description
Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompas...
How the Company Makes Money
Newron primarily makes money through (1) partnering and licensing arrangements for its drug assets and (2) product-related income where applicable. A key component has been collaboration income tied to commercialization of its Parkinson’s disease-...
Newron Pharmaceuticals SpA Earnings Call Summary
Earnings Call Date:Mar 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Sep 22, 2026
Earnings Call Sentiment Positive
The call presented multiple strong positive developments: validation from a top-tier partner (Eisai) and EUR 48m collected, a large global pivotal program across >1,300 patients with significant Phase III/Phase II efficacy signals (8A: PANSS p=0.006; CGI-S p=0.037), an improved IP position (European crystalline patent and potential U.S. grant to extend exclusivity to 2044), robust safety/tolerability and clear commercial expansion potential. Management has secured non-dilutive runway and delayed debt service to mid-2028. Principal risks flagged were operational recruitment challenges, parts of funding conditional on positive results (EUR 12m), pending U.S. patent timing, and the fact that a NASDAQ uplisting is not currently achievable without further progress. On balance the highlights (clinical validation, funding, IP progress, safety, analyst coverage) substantially outweigh the lowlights, though the company remains dependent on upcoming pivotal readouts and execution.Positive Updates
Strategic Partnership and Initial Funding Secured
December 2024 licensing deal with EA (Eisai Group) validated evenamide and generated EUR 48 million collected to advance Phase III. New funding agreement provides access up to EUR 38 million (EUR 15m already in bank, EUR 11m expected before year-end with no milestones attached, and EUR 12m conditional on positive pivotal results). European Investment Bank loan repayments delayed to no earlier than June 2028, improving near-term liquidity runway.
Negative Updates
Reliance on Upcoming Pivotal Readouts and Conditional Funding
A material portion of near-term funding (EUR 12 million) is conditional on positive pivotal results by year-end; management excluded this conditional amount from cash guidance. Success timelines and some funding are therefore contingent on trial outcomes.
Read all updates
Q4-2025 Updates
Positive
Negative
Strategic Partnership and Initial Funding Secured
December 2024 licensing deal with EA (Eisai Group) validated evenamide and generated EUR 48 million collected to advance Phase III. New funding agreement provides access up to EUR 38 million (EUR 15m already in bank, EUR 11m expected before year-end with no milestones attached, and EUR 12m conditional on positive pivotal results). European Investment Bank loan repayments delayed to no earlier than June 2028, improving near-term liquidity runway.
Read all positive updates
Company Guidance
Guidance from the call was that Newron expects 12‑week pivotal readouts within 2026 and aims to complete enrollment in ENIGMA‑TRS‑1 (a 600‑patient, 52‑week TRS study with a 12‑week primary endpoint) by end‑August 2026 with primary results by year‑end and a likely NDA filing in Q1–Q2 2027; ENIGMA‑TRS‑2 (a shorter 12‑week pivotal) may report topline in Q4‑26/early‑Jan and announcements will be separate. Management said the company is running three pivotal studies (>1,300 patients worldwide), has the cash to reach the 12‑week readouts (EUR 48m received from the Eisai deal plus access to up to EUR 38m new financing: EUR 15m already in the bank, EUR 11m expected before year‑end, and EUR 12m conditional on positive pivotal results), and that a positive readout would likely unlock the conditional EUR 12m and extend runway into late‑2027 (an extra ~6–9 months per management). The European Investment Bank loan repayments were deferred to not before June 2028, shareholders will vote on April 23, 2026 on a 15% capital increase (and 5% for option plans) to support additional indications/uplisting, and Newron noted ~20.8m shares outstanding, ~1.6m warrants, daily turnover of ~0.7–1% of the stock and a pending crystalline‑form composition‑of‑matter patent that could extend exclusivity to 2044 (current US COM to 2035; process patents to 2042).Newron Pharmaceuticals SpA Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
18
Very Negative
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 19.13M | 51.39M | 9.06M | 6.09M | 5.76M |
| Gross Profit | 19.13M | 51.39M | 9.06M | 6.09M | 5.76M |
| EBITDA | -4.55M | 25.94M | -11.83M | -13.32M | -11.92M |
| Net Income | -13.24M | 15.84M | -16.22M | -17.49M | -14.90M |
Balance Sheet | |||||
| Total Assets | 40.02M | 63.91M | 25.87M | 37.20M | 50.49M |
| Cash, Cash Equivalents and Short-Term Investments | 28.85M | 9.83M | 12.60M | 22.77M | 34.59M |
| Total Debt | 38.13M | 50.47M | 48.41M | 45.66M | 43.08M |
| Total Liabilities | 51.15M | 62.45M | 55.77M | 51.23M | 47.38M |
| Stockholders Equity | -11.13M | 1.46M | -29.91M | -14.03M | 3.11M |
Cash Flow | |||||
| Free Cash Flow | 32.51M | -17.63M | -10.15M | -11.11M | -11.46M |
| Operating Cash Flow | 32.56M | -17.61M | -10.14M | -11.09M | -11.45M |
| Investing Cash Flow | -13.75M | 3.16M | 3.25M | -317.00K | 8.42M |
| Financing Cash Flow | -13.52M | 15.05M | -192.00K | -186.00K | 14.83M |
Newron Pharmaceuticals SpA Technical Analysis
Negative
16.44
Price Trends
14.09
Negative
16.02
Negative
16.19
Negative
Market Momentum
-0.61
Negative
38.82
Neutral
52.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:NWRN, the sentiment is Negative. The current price of 16.44 is above the 20-day moving average (MA) of 12.69, above the 50-day MA of 14.09, and above the 200-day MA of 16.19, indicating a bearish trend. The MACD of -0.61 indicates Negative momentum. The RSI at 38.82 is Neutral, neither overbought nor oversold. The STOCH value of 52.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:NWRN.
Newron Pharmaceuticals SpA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF622.97M | 19.16 | ― | ― | 11.43% | -48.80% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | CHF254.25M | -19.94 | ― | ― | -63.05% | -187.61% | |
50 Neutral | CHF1.48B | -6.69 | ― | ― | 35.80% | 24.01% | |
44 Neutral | CHF238.72M | -4.39 | -301.13% | ― | 97.32% | -11.07% | |
43 Neutral | CHF125.97M | -2.01 | -51.05% | ― | -100.00% | 9.23% |
* General Sector Average
CH:NWRN
Newron Pharmaceuticals SpA
12.20
5.09
71.59%
CH:MOLN
Molecular Partners AG
3.09
0.19
6.74%
CH:BSLN
Basilea Pharmaceutica
51.30
2.45
5.02%
CH:IDIA
Idorsia Ltd
5.68
3.78
198.68%
CH:SANN
Santhera Pharmaceuticals Holding
15.94
4.14
35.08%
CH:XLS
Xlife Sciences Ltd.
25.20
5.55
28.24%
Newron Pharmaceuticals SpA Corporate Events
FDA halts U.S. recruitment in Newron’s key schizophrenia trial after patient death
Apr 29, 2026
Newron Pharmaceuticals said the U.S. Food and Drug Administration has ordered a halt to new patient enrolment at U.S. sites in its Phase III ENIGMA-TRS 2 trial of Evenamide for treatment-resistant schizophrenia, after the company reported a sudden...
Newron Shareholders Back Board Changes at 2026 General Meeting
Apr 23, 2026
Newron Pharmaceuticals reported that shareholders at its 2026 General Meeting approved all items on the ordinary agenda, including the election of George Garibaldi and Paolo Zocchi as new independent, non-executive board members, while the extraor...
Newron bolsters finances as Evenamide enters pivotal global Phase III
Mar 24, 2026
Newron Pharmaceuticals reported a transformative 2025 marked by major advances in its Evenamide program, including regulatory approval and global initiation of the ENIGMA-TRS Phase III trials for treatment-resistant schizophrenia, expanded intelle...
Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul
Mar 24, 2026
Newron reported 2025 as a landmark year, driven by progress in its Evenamide program, including regulatory approval and initiation of the pivotal ENIGMA-TRS phase III trials in treatment-resistant schizophrenia across multiple regions. Partner EA ...
Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress
Mar 20, 2026
Newron Pharmaceuticals will showcase new data on its lead drug candidate Evenamide at the 2026 Schizophrenia International Research Society congress in Florence, highlighting glutamatergic modulation as a potential approach for treatment-resistant...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.